Bulk Pharmaceutical API Sources for halofantrine hydrochloride

Bulk Pharmaceutical API Sources for halofantrine hydrochloride

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		37392
MolPort		MolPort-005-942-171
ABI Chem		AC1L1XMK

Bulk Active Pharmaceutical Ingredient (API) Sources for: Halofantrine Hydrochloride

Last updated: July 29, 2025

---

Introduction

The sourcing of Active Pharmaceutical Ingredients (APIs) like halofantrine hydrochloride involves a complex landscape influenced by regulatory standards, manufacturing quality, supply chain stability, and geopolitical considerations. Halofantrine hydrochloride, an antimalarial agent developed in the latter half of the 20th century, remains critical in certain treatment regimes despite its limited current use—primarily due to safety concerns over cardiotoxicity. Nonetheless, its production and supply are vital for fulfilling specialized needs and research purposes. This report analyzes the global landscape of bulk API suppliers for halofantrine hydrochloride, emphasizing their geographic distribution, manufacturing capacities, regulatory credentials, and market outlooks.

---

Overview of Halofantrine Hydrochloride

Developed by GlaxoSmithKline (GSK) in the 1980s, halofantrine hydrochloride functions by disrupting the parasitic lifecycle through interference with mitochondrial activity. Its clinical utility is primarily for chloroquine-resistant malaria strains. Despite declining worldwide use—largely replaced by artemisinin-based therapies—its production persists for research, niche treatments, and in regions with limited access to newer drugs.

Manufacturing halofantrine hydrochloride requires specialized synthetic pathways, involving multi-step chemical processes that demand adherence to Good Manufacturing Practices (GMP). Consequently, sourcing reliable manufacturers is non-trivial, and the API’s supply chain bears scrutiny for quality and regulatory compliance.

---

Global API Manufacturing Landscape

Major API Producers

Historically, API manufacturing for pharmaceuticals like halofantrine hydrochloride has been concentrated in regions with established chemical synthesis infrastructure: primarily China, India, and certain European countries. These regions offer the capacity for high-volume production, cost efficiencies, and adherence to global regulatory standards.

China remains a dominant contributor to global API supply, with multiple GMP-certified manufacturers offering APIs across therapeutic categories. Chinese API suppliers are known for their substantial capacities, though variability in quality control and regulatory transparency can pose risks. Companies such as Zhejiang Huahai Pharmaceutical and Zhejiang Haisheng Pharmaceutical Group have broad portfolios, occasionally including antimalarials or related compounds.

India boasts an extensive API manufacturing sector, driven by pharmaceutical hubs in Gujarat, Maharashtra, and Telangana. Companies like Cadila Healthcare and Natco Pharma, while primarily focused on more prevalent drugs, have the infrastructure to produce complex APIs like halofantrine hydrochloride under licensing or co-development agreements.

Europe, especially Germany and Switzerland, offers high-quality, GMP-compliant APIs for niche or high-value pharmaceuticals. Suppliers here, such as Novartis or specialized synthesis firms, prioritize stringent quality standards, though at higher price points and potentially limited capacity.

Specialized and Niche Suppliers

Given halofantrine hydrochloride's specific therapeutic and research applications, some API producers focus solely on niche APIs, often serving the academic, governmental, or biopharmaceutical sectors. These suppliers maintain stringent quality assurance processes, facilitating procurement for clinical trials or regulatory submissions.

Regulatory and Certification Considerations

Sourcing API for pharmaceuticals requires compliance with international standards, notably:

• GMP Certification: Mandatory for APIs intended for human use.
• ISO Certification: Ensures quality management systems.
• Accreditations such as EDQM or US FDA registration: Bolster supply chain reliability and traceability.

While Chinese and Indian manufacturers frequently possess GMP certification recognized globally, verification of current compliance and audit readiness remains critical for procurement.

Supply Chain and Market Dynamics

• Supply Stability: The API market for halofantrine hydrochloride is relatively niche, limiting stockpiles or predictable supply chains. Fluctuations in demand or manufacturing disruptions can lead to shortages.

• Pricing Factors: Cost varies significantly based on geographical origin, API purity grade, and batch size, with Chinese suppliers generally offering lower prices but with heightened due diligence.

• Regulatory Barriers: Import restrictions, tariffs, and registration requirements further influence sourcing strategies, especially in highly regulated markets like the US and Europe.

Emerging Trends and Challenges

• Quality Assurance: Increased emphasis on quality and traceability is pushing purchasers toward certified suppliers.
• Manufacturing Consolidation: Some smaller players exit markets or consolidate, impacting the supply pool.
• Regulatory Reclassification: The shift towards newer antimalarials diminishes demand for older APIs like halofantrine hydrochloride, potentially reducing manufacturing activity further.

---

Conclusion

While the global market for halofantrine hydrochloride API is niche, reliable, high-quality sources primarily reside in China, India, and select European countries. Buyers must prioritize suppliers with current GMP certification, robust quality control, and supply chain transparency. The landscape's future hinges on regulatory trends, clinical needs, and the ongoing demand for specialized antimalarials. Strategic sourcing, coupled with rigorous supplier verification, remains paramount to secure quality API supplies.

---

Key Takeaways

• The primary sources of halofantrine hydrochloride API are China, India, and Europe, with China leading in capacity.
• Suppliers must possess current GMP certification and demonstrate regulatory compliance.
• Market supply remains niche, influenced by decreasing global demand and shifting treatment standards.
• Due diligence in vendor qualification and quality assurance is essential for procurement.
• The API’s niche status warrants continuous market monitoring to mitigate supply risks and capitalize on emerging opportunities.

---

FAQs

1. What are the top countries producing halofantrine hydrochloride API?
China and India are the leading regions, housing most manufacturers capable of producing the API at commercial scales under GMP standards.

2. How can buyers verify the quality of halofantrine hydrochloride API suppliers?
Verification involves reviewing GMP certification, inspecting quality control documentation, auditing manufacturing facilities, and confirming compliance with international regulatory standards like ISO and EU certifications.

3. Is there an increased risk of supply shortages for halofantrine hydrochloride API?
Yes. As the global clinical demand declines due to safety concerns and alternative therapies, manufacturing capacity reduces, increasing potential supply disruptions.

4. Can I procure halofantrine hydrochloride API from pharmaceutical-grade suppliers for research?
Yes, suppliers catering to research institutions and clinical research organizations can provide pharmaceutical-grade APIs, often with strict quality assurance protocols.

5. What are the regulatory considerations when importing halofantrine hydrochloride API?
Importers must ensure the API complies with local regulations, including validation of GMP certification, adherence to import/export controls, and proper documentation to meet pharmacopoeial standards.

---

References

[1] World Health Organization. Guidelines for the Procurement and Supply of Medicine. WHO, 2017.
[2] U.S. Food and Drug Administration. API Drug Master Files. FDA, 2022.
[3] Chemical & Pharmaceutical Industry Reports. Global API Market Trends, 2023.
[4] European Directorate for the Quality of Medicines & HealthCare (EDQM). Certificate of Suitability (CEP): Guidance.
[5] PharmaCompass. API Manufacturer Directory. 2023.

---

Note: This report was prepared based on publicly available data as of early 2023. The API supply chain is subject to ongoing regulatory, geopolitical, and market shifts.